AbCellera (ABCL) Director Hayden Michael R Buys 53,613 Shares

What Happened Hayden Michael R, a director of AbCellera Biologics Inc. (ABCL), reported a purchase of 53,613 shares on August 24, 2026. The filing shows a weighted-average price of $10.64, for a total reported value of $570,442. The transaction is reported as a purchase (code P), which is a direct buy of shares rather than an option exercise or grant.

Key Details

• Transaction date: 2026-08-24. Reported as purchase (P).
• Price: weighted-average $10.64; actual trades ranged from $10.49 to $10.70 (report says full per-trade details available on request).
• Shares acquired: 53,613; total value reported: $570,442.
• Shares owned after transaction: not specified in the filing.
• Ownership note (footnote): the shares are held by Genworks 2 Consulting, Inc.; the reporting person’s spouse has sole voting and investment power over those shares and the reporting person disclaims beneficial ownership except for any indirect pecuniary interest.
• Filing timeliness: reported and filed on 2026-08-24 (no late-filing indication).

Context This was a direct purchase rather than an option exercise or award. Because the shares are held by an entity (Genworks 2) controlled for voting/investment purposes by the reporting person’s spouse — and the reporting person disclaims beneficial ownership — this filing may reflect an acquisition by a related-party entity rather than a personal, directly controlled stake. Retail investors should note the purchase is factual insider activity but avoid inferring management intent beyond the reported facts.